Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort

Kenmogne, VLTakalani, AMTNweke, EETakundwa, Mutsa MFabian, JuneMaher, HeatherDu Toit, JustinPhilip-Cherian, VFru, PFGovindaraj, Deepak BT2023-12-112023-12-112023-10Kenmogne, V., Takalani, A., Nweke, E., Takundwa, M.M., Fabian, J., Maher, H., Du Toit, J. & Philip-Cherian, V. et al. 2023. Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort. Hematology, Transfusion and Cell Therapy, 45(3). http://hdl.handle.net/10204/133832531-13792531-1387https://doi.org/10.1016/j.htct.2023.09.053http://hdl.handle.net/10204/13383Our objective is to develop a functional precision medicine platform designed to directly identify tailored drug regimens that target individual patient cancer cells and give benefit to the same donors by supporting clinical decision-making. We demonstrate our ex vivo drug sensitivity screening platform for precision medicine using Leukaemia and Multiple Myeloma samples from a South African patient cohort as proof of concept.FulltextenDrug sensitivityEx vivoLeukaemiaMyelomaPatient cohortEstablishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohortArticleKenmogne, V., Takalani, A., Nweke, E., Takundwa, M. M., Fabian, J., Maher, H., ... Govindaraj, D. (2023). Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort. Hematology, Transfusion and Cell Therapy, 45(3), http://hdl.handle.net/10204/13383Kenmogne, VL, AMT Takalani, EE Nweke, Mutsa M Takundwa, June Fabian, Heather Maher, Justin Du Toit, V Philip-Cherian, PF Fru, and DBT Govindaraj "Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort." Hematology, Transfusion and Cell Therapy, 45(3) (2023) http://hdl.handle.net/10204/13383Kenmogne V, Takalani A, Nweke E, Takundwa MM, Fabian J, Maher H, et al. Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort. Hematology, Transfusion and Cell Therapy, 45(3). 2023; http://hdl.handle.net/10204/13383.TY - Article AU - Kenmogne, VL AU - Takalani, AMT AU - Nweke, EE AU - Takundwa, Mutsa M AU - Fabian, June AU - Maher, Heather AU - Du Toit, Justin AU - Philip-Cherian, V AU - Fru, PF AU - Govindaraj, DBT AB - Our objective is to develop a functional precision medicine platform designed to directly identify tailored drug regimens that target individual patient cancer cells and give benefit to the same donors by supporting clinical decision-making. We demonstrate our ex vivo drug sensitivity screening platform for precision medicine using Leukaemia and Multiple Myeloma samples from a South African patient cohort as proof of concept. DA - 2023-10 DB - ResearchSpace DP - CSIR J1 - Hematology, Transfusion and Cell Therapy, 45(3) KW - Drug sensitivity KW - Ex vivo KW - Leukaemia KW - Myeloma KW - Patient cohort LK - https://researchspace.csir.co.za PY - 2023 SM - 2531-1379 SM - 2531-1387 T1 - Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort TI - Establishment of ex vivo drug sensitivity screening platform for leukaemia and multiple myeloma using a South African patient cohort UR - http://hdl.handle.net/10204/13383 ER -27195